LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress, and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology.
LB-100 is a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology—activation lethality—that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
The acquisition of Liora Technologies Europe Ltd. adds an innovative dimension to LIXTE’s pipeline. Through its wholly owned subsidiary, LIXTE is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.
The company also strengthened its financial position by raising more than $11 million, which is expected to support ongoing clinical trials and operational activities. The full press release is available at https://ibn.fm/LP6QH.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Additional information can be found at www.lixte.com.
This filing underscores LIXTE’s commitment to advancing its pipeline and expanding its technological capabilities, positioning the company for potential breakthroughs in cancer treatment.
